chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient reports swelling and pain at the vaccine injection site following injection that resolved in two days. Two days following the injection, she developed deltoid and shoulder pain with left upper extremity abduction, forward flexion and external rotation and positive impingement signs. She reports this started 2 or 3 days following the vaccine injection and have gotten progressively worse since.
Uncontrollable shaking for approximately 2hrs, leading into severe migraine and entire body ache for 24 hours. Possible fever but was unable to get out of bed to get a thermometer.
Patient c/o feeling dizzy, sore arm, fatigue and nausea. Area warm to touch, and CV progressed to fever and swelling. Seen by MD 9-14-16 Prednisone 50mg x 5 days.
ED presentation to facility on 04/12/2021 and noted that she was having left-sided dysesthesias and was having difficulty with increasing ataxia.  She was seen by Stroke Neurology and underwent ultrasound-guided cannulation of the right femoral artery with subsequent cerebral angiography. After supplying the right ophthalmic artery, the right internal carotid artery was completely occluded. There were no collaterals. She had been seen by Physical and Occupational Therapy and it was felt that she would benefit from inpatient rehabilitation and she was transferred. ED visit and hospital admission within 6 weeks of receiving the COVID vaccine.
1 of 3 pts vaxed devel inject site reactions which began 4-5 hrs following vax; arms was very painful, hot to the touch 7 erythema was approx 7" in diameter; tx w/Augmentin;
This spontaneous report as received from a registered nurse refers to a 13-month-old patient of unknown gender. The patient's medical history was not reported. On 29-AUG-2016, the patient was inadvertently vaccinated with an expired dose of (wistar ra 27-3) M-M-R II lot # K011189, expiration date 12-AUG-2016, subcutaneous (therapy type was not reported). Concomitant medications were not reported. No adverse effects were reported. Additional information has been requested.
This spontaneous report as received from a medical assistant refers to unspecified patients of unknown age and gender. It was reported that since 29-AUG-2014 unknown number of patients were administered GARDASIL (dose, route of administration, lot numbers and expiration dates were not reported) which was improperly stored. No adverse effects reported. This is one of several reports from the same source. Additional information has been requested.
Headache, Arthralgia, NauseaVomiting, chills Narrative:  Other Relevant History:
Sunday I had a cough and tested self on Monday. I tested positive twice. I started to have muscle fatigue and brain fog. My temperature was at 100 today. I have also been experiencing dizziness. I also had loss of appetite in the beginning which has now improved. I do still have a cough and I waiting for the hospital to call back to set up an appointment for Monoclonal antibodies infusion.
high pitch cry approx 45mins to 1 hr afternoon of vax 7MAR95, rt leg appeared tender to touch, warm to touch;
And I had a terrible time with both the other doses; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (And I had a terrible time with both the other doses) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (And I had a terrible time with both the other doses). At the time of the report, VACCINATION COMPLICATION (And I had a terrible time with both the other doses) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No relevant concomitant medications were reported. No treatment information was provided.   This case was linked to MOD-2022-437608, MOD-2022-437619 (Patient Link).   Reporter did not allow further contact
This case was reported by a consumer via call center representative and described the occurrence of stomach pain in a 52-year-old female patient who received SHINGRIX for prophylaxis. Concomitant products included SHINGRIX. On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced stomach pain, injection site pain, injection site erythema, fever, chills, exhaustion, sickness, injection site swelling and injection site warmth. Rechallenge with SHINGRIX was positive. On an unknown date, the outcome of the stomach pain, injection site pain, injection site erythema, fever, chills, exhaustion, sickness, injection site swelling and injection site warmth were recovered/resolved. It was unknown if the reporter considered the stomach pain, injection site pain, injection site erythema, fever, chills, exhaustion, sickness, injection site swelling and injection site warmth to be related to SHINGRIX. Additional details were provided as follows: The patient expereinced stomach pain, injection site pain, injection site erythema, fever, chills, exhaustion, sick and hot swollen arm at the vaccination site after 2nd dose of SHINGRIX. This case is linke dto case US2019000403, same patient.
pt recvd vax JAN93 & w/in 24 hrs pt devel a swollen muscle that lasted for 4 to 5 days; No further details were provided;
Patient completed COVID-19 Pfizer series in February 2021. Presented to ED with symptoms of cough, congestion, sore throat, and intermittent diarrhea. 8/9 tested positive for COVID-19 treatment. Re-presented in ED 9/7 with loss of taste and smell, shortness of breath, and decreased appetite, and another positive COVID test. Not admitted and sent home after 1 dose of dexamethasone.
did not receive his 2nd dose; This case was reported by a pharmacist via other manufacturer and described the occurrence of incomplete course of vaccination in a male patient who received HAV (Havrix) for prophylaxis.   Previously administered products included HAVRIX (1st dose received 13 months ago from the date of reporting).   On an unknown date, the patient received the 2nd dose of Havrix. On an unknown date, unknown after receiving Havrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional details were reported as follows: The age at vaccination was not applicable for this report. Pharmacist reported a patient was supposed to get his 2nd dose of 12 months later but the patient did not receive his 2nd dose of Havrix till the time of reporting for unknown reasons which led to incomplete course of vaccination.  The reporter wanted to know if the patient could get a dose of VAQTA now instead of Havrix. No additional adverse event were reported.  No product quality complaint PQC reported. No further information was provided. No contact details were reported.
Full body rash broke out the morning after I got the shot. Went to the ER and was treated with topical steroid treatment. Resolved in about a month.  Chest pain ongoing since I got the shot. Treated with oral steroid after first episode and am now on Colchicine
1st dose - nothing 2nd dose - I had the regular slight fever and sore arm for a day or so.  That was not a big deal at all.  After the swelling went down from the 2nd shot, I have had tingling-like pins and needle feeling about 5-10 times a day.
Itchy throat, 2 inch red wheel around injection site that became larger-zyrtec and ice applied in urgent care. Followed by itching all over and epinephrine administered in urgent care.
Case number PHEH2015US001244, is an initial spontaneous report from a health care professional received on 13 Jan 2015. This report refers to a 19-years-old male patient. Historical conditions were not reported. No concomitant medication was reported. He was administered only MenCYW-135 liquid component of MENVEO (batch number: X14023) without being reconstituted with MenA lyophilized conjugate intramuscularly on 09 Jan 2015. No adverse event was reported following the administration error.
Patient had a grand mal seizure in lobby at doctors office at visit where he received both vaccines.    He has a known history of seizures.  The seizure lasted 4 minutes and was without loss of consciousness.  Patient did not hurt himself and regained awareness and stated he was fine afterwards and was assessed by nursing and primary care provider.
Patient reports typical soreness, redness following AVA vaccinations in sometime in 1999 with slow worsening of symptoms w/each sequential vaccination.  Approximately 6 months following his fourth AVA vac in 1999 he complained of slow progression of bilateral grinding knee pain L>R patella. Activity, walking up/down stairs etc aggravated symptoms.  A full orthopedic eval w/arthroscopy for questionable hairline fx vs medial meniscus degeneration were ineffective.  He continues to have pain and is concerned AVA may be a factor. Medical record sttes ataxia, bone disease.
body aches; arm hurts; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (body aches) and PAIN IN EXTREMITY (arm hurts) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history reported).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MYALGIA (body aches) and PAIN IN EXTREMITY (arm hurts). At the time of the report, MYALGIA (body aches) and PAIN IN EXTREMITY (arm hurts) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
PT STATES HER ARM FROM SHOULDER TO ELBOW WAS SWOLLEN, RED,  HOT AND PAINFUL FOR 3 DAYS AND SORE FOR A WEEK AFTER. PT STATES SHE TOOK BENADRYL AND ASPIRIN. DID NOT NOTIFY ANYONE UNTIL TODAY WHEN SHE HEARD THAT SHE NEEDED TO ON THE RADIO.
Hard red lump at injection site, RT thigh, Varicella and Hep A given in that thigh. A photograph was taken of the adverse event.   Treatment is: continue taking Vitamin D, follow up at home  and parents are to call if it is getting larger or if it is getting worse in any way.
26Jan90 pt vax w/ Hep B; 27Aug90 exp paresthesia of upper extremities assoc w/ diminished pinprick sensation.  Pre-existent neck pain worsened w/ mild percussion tenderness + pain at extremes of motion. 27Oct90 devel herpes zoster
CAN'T WALK AT TIMES; VERY UNSTEADY WHEN WALKING; STANDING ON ONE LEG IMPOSSIBLE; MUSCLE CONTRACTED AND WON'T LET GO; MUSCLE WEAKNESS; MUSCLE PAIN; This spontaneous report received from a patient concerned a 61 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included arthritis in knees.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808978, expiry: UNKNOWN) dose was not reported, administered on 25-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 25-APR-2021, the subject experienced can't walk at times. On 25-APR-2021, the subject experienced very unsteady when walking. On 25-APR-2021, the subject experienced standing on one leg impossible. On 25-APR-2021, the subject experienced muscle contracted and won't let go. On 25-APR-2021, the subject experienced muscle weakness. On 25-APR-2021, the subject experienced muscle pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from can't walk at times, very unsteady when walking, standing on one leg impossible, muscle pain, muscle contracted and won't let go, and muscle weakness. This report was non-serious.
pt recv vax & devel nasal congestion, fever, sore throat w/pseudomembranous coating & an elevated erythrocyte sed rate;MD suspects diphtheria, but dx had not been confirmed as of 21APR98;
Swelling in the left upper lip. Tx BENADRYL 25 mg PO Q 6h PRN. BENADRYL 50mg PM
pt recv vax in AM;rxn began w/in a few hr;temp reached 104;was lethargic w/body aches & severe swelling of the leg;pt would not walk on this leg & dragged it along;sx lasted 5-7 days;given APAP & cool compresses to the site
This case was reported by a  nurse via call center representative and described the occurrence of injection site rash in a 4-year-old female patient who received KINRIX (batch number 2A947, expiry date 31st OCTOBER 2017). On an unknown date, the patient received KINRIX. On an unknown date, an unknown time after receiving KINRIX, the patient experienced injection site rash. The patient was treated with non-drug therapy (Cold Compress) and cetirizine. On an unknown date, the outcome of the injection site rash was recovered/resolved. The reporter considered the injection site rash to be related to KINRIX. Additional details were provided as follows: The patient's age at vaccination was not reported. The reporter stated that, the patient experienced rash that started at the injection and spread over the entire deltoid.
Narrative:  patient received vaccine at hospital, but treatment and documentation at ER (self presented). Per outside hospital ER, admitting diagnosis: embolism without acute cor pulmonale (8-27-21)
Wed Apr 17, 2013 1625 pm. Mother at window with child, states blotchy rash on face and "breathing funny" At time of assessment, somewhat pale, with blotchy rash on face, not hive-like. RR-40/HR 156. Observed for 20-25 minutes, responsive when moved or stimulated. Rash faded. Mother advised to observe closely tonite, call if any issues, however then doctor. Gave her his cell # to call. Discussed s/s reaction to TYLENOL and DTP, esp to pertussis component of vaccine, mother also has VIS. Mother comfortable with plan of care. Also informed mother that anyone in contact with child should consider having TDAP as we may not vaccinate him with pertussis in the future-including 10 yr old sibling who could receive BOOSTRIX. ADDENDUM NOTE: 447 pm. after vaccines child cried very vigorously then fell asleep. On way to car a blotchy rash was noted so came back in. Pulse ox was 100% and lungs clear. Observed for 20-25 min, rash faded. Of note TYLENOL given by mom for shots red dye so not sure if from dye or pertussis. Will consider deferral of pertussis and use of dye free TYLENOL in future. All adults in contact advised to get pertussis vaccination in case we defer next time.
Angioedema, SkinRash & UrticariaPruritus Narrative: Patient reports symptom resolution within 30 minutes of diphenhydramine self-administration.
blood sugar rise; This is a spontaneous report received from a non-contactable reporter (Consumer or other non HCP). The reporter is the patient.  A female patient received bnt162b2 (Pfizer-BioNTech COVID-19) (Batch/Lot number: unknown) as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BLOOD GLUCOSE INCREASED (non-serious), outcome "unknown", described as "blood sugar rise". Relevant laboratory tests and procedures are available in the appropriate section. Additional information:patient have blood sugar rise after she had the shots each time.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101742491 same vaccine, AE and different patient;US-PFIZER INC-202101742407 same vaccine, AE and different patient;US-PFIZER INC-202101741528 same patient, different dose/AE.;US-PFIZER INC-202101744009 same vaccine, AE and different patient;US-PFIZER INC-202101744010 same vaccine, AE and different patient
- 2:00 pm on 3-13-21; fatigue, chills; felt better after taking two hour nap - 8:00 pm on 3-13-21; stomach cramps, diarrhea, extreme weakness, loss of consciousness (fainted); gradually got better over next seven days
Well Pt was late to work blaming the pain from inj. She stated immediate pain and swelling which has continued to get worse since then. Pt said she has under-arm nerve pain. She said pain is "oozing into her hand and refuses to move or use her hand and arm so Tdap toxins don't get into the rest of her body".
No additional AE or PQC reported; HCP reported a patient was administered their first dose of ROTATEQ at 16 weeks and 3 days of age. Caller was unable to provide any further clarifying details as she was not the primary HCP for this patient. No additional AE or PQC reported. No addit; This spontaneous report was received from a pharmacist and a physician and physician referring to a16-week-old infant patient of unknown age. Patients' concurrent conditions, medical history, concomitant medications and drug reaction/allergies were not reported.  On 24-FEB-2023, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, orally for prophylaxis (strength, lot #, and expiry date were not provided) (product administered to patient of inappropriate age). No additional adverse event (AE) reported (no AE). The physician was very upset and thought she had done something wrong after receiving a vaccine -Device form. The physician would like verification of the original conversation where she was told it was alright to administer the product and would contact again when she had the patient information.
Pt given Tdap vs Td at age 72. No adverse reaction noted at this time.
Pt had itchy eyes, coughing and increased dyspnea.  She has a hx of allergic reactions and this began much like other reactions she has experienced in the past.  She was aware of the change and called for help.  She was given benadryl and 125 of solumedrol en route to the ER.  Pts SpO2 dropped to 95% and was placed on NC at 4LPM.  Pt states her eyes still itch and she feels the need to clear her throat, but no longer feels the shortness of breath.
Shoulder joint pain in the right shoulder, mild at first but worsening day by day culminating on 9/5/22.
Small fiber neuropathy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 57 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SMALL FIBRE NEUROPATHY (non-serious), outcome "unknown", described as "Small fiber neuropathy". Additional information: This is report 2 of 2. As the caller was completing a report on behalf of himself in-regards to the Pfizer COVID vaccine, the caller mentions he went on the website. The caller states it was a 57-year-old women with the same exact symptoms he had. No further details were provided or obtained.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Severe local inflammation to include entire left arm and fingers after receiving 2nd Anthrax shot, followed by 2 years ongoing chronic, episodic musculo-skeletal and physical symptoms. Patient claims she came back on 14 Jul 04 (next day after Shot #2) to discuss reaction to the shot, but no documentation is in her medical record of a VAERS form, and the person who gave her the 2nd shot, states that no severe reaction was present. Patient recieved a 3rd Anthrax shot on 27 Jul 04. Headaches, joint pain, and fatigue still persists since 3rd Anthrax shot.
Extreme chills starting at 2:40 a.m.  Tired and listless feeling for the rest of the day and into the next day. It was the same symptoms as the Coronavirus infection from November.
This case was reported by a physician and described the occurrence of shoulder pain in a subject of unspecified age and gender who was vaccinated with FLUARIX (GlaxoSmithKline). On an unspecified date, the subject received a dose of FLUARIX (unknown) and experienced shoulder pain and shoulder tendonitis. At the time of reporting the outcome of the events were unspecified.
PATIENT ADMITTED TO HOSPITAL WITH SOB  VACCINATED IN MAY AND JUNE 2021 STILL INPATIENT
tested positive for Covid-19 virus; tested positive for Covid-19 virus; This is a spontaneous report from a contactable consumer (patient). A 57-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE lot number: EL3247) via an unspecified route of administration, administered on the right arm on 31Mar2021 21:15 at a single dose for COVID-19 immunisation. Medical history included diabetes. Concomitant medications included insulin lispro (HUMALOG), lisinopril, simvastatin, amitriptyline and semaglutide (OZEMPIC). On 13Apr2021 10:00, the patient tested positive for Covid virus. Nasal swab done post vaccination on 13Apr2021: COVID test result: Positive. The event resulted to a Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care. Prior to vaccination, the patient was not diagnosed with COVID-19. The facility where the vaccine was administered was in a workplace clinic. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Therapeutic measures were taken as a result of the events which included hydrocodone/chlorphen Suspension, Tylenol. Outcome of the event was recovering.
The pt experienced the typical soreness for 3-4 days. One week later the arm became very sore and weak. The pt complained of discomfort with lifting arm or when reaching around to back. Warm compresses were used for 48 hours. Dx of myositis was made.
Light red rash about 2.5 x 4" around vaccination site and itchy.  Took about a week to clear up.
PATIENT DEVELOPED FATIGUE, INANITION, WEAKNESS,  WORSENED DYSPEA ABOVER HER BASELINE.  WAS ADMITTED TO HOSPITAL FROM 5/5/2021 TO 5/10/2021 AND TREATED FOR COPD EXACERBATION AND DESCRIBES SEVERE WEAKNESS SHE SHOULD NOT LIFT UP HER HEAD OR PICK UP HER LEGS.  NOW HAS DIFFICULTY WALKING WITH HER LEGS GIVING WAY.  EXAM 5/13/2021 SHOWS WEEZES ANTERIORLY , DIFFUSE ECCHYMOSES AT PHLEBOTOMY AND CUFF SIZES AND DIFFUSE HEMOSIDERIN VENOUS STASIS CHANGES LEGS AND 1/2 PT BILATERALLY.